ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SVA Sinovac Biotech Ltd

6.47
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sinovac Biotech Ltd NASDAQ:SVA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.47 6.47 6.00 0 01:00:00

Sinovac to Participate in Morgan Stanley Global Healthcare Conference

10/09/2015 11:00am

PR Newswire (US)


Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sinovac Biotech Charts.

BEIJING, Sept. 10, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate the Morgan Stanley Global Healthcare Conference, to be held at the Grand Hyatt Hotel in New York City from Wednesday September 16 to Friday September 18, 2015. Please contact your Morgan Stanley representative for conference registration information and to schedule a meeting with the Company.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial. The Company is currently developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to Mexico, Mongolia, Nepal, and the Philippines, and was recently granted a license to commercialize its hepatitis A vaccine in Chile. For more information, please visit the Company's website at www.sinovac.com. 

Contact
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com

ICR Inc.
Bill Zima
Phone: +1 (646) 308-1707
Email: william.zima@icrinc.com

Katherine Knight
Phone: +1 (646) 277-1276
Email: katherine.knight@icrinc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sinovac-to-participate-in-morgan-stanley-global-healthcare-conference-300140676.html

SOURCE Sinovac Biotech Ltd.

Copyright 2015 PR Newswire

1 Year Sinovac Biotech Chart

1 Year Sinovac Biotech Chart

1 Month Sinovac Biotech Chart

1 Month Sinovac Biotech Chart

Your Recent History

Delayed Upgrade Clock